Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Current diagnosis of Chronic Kidney Disease, either receiving or not receiving dialysis~* Anemic, with two consecutive screening hemoglobin values drawn at least 7 days apart \< 11.0 g/dL~* Transferrin saturation (Tsat) greater than or equal to 20%~Exclusion Criteria:~* Any erythropoiesis stimulating agent (ESA) use within 12 weeks prior to randomization~* other hematologic disorders~* upper or lower gastrointenstinal bleeding within 6 months prior to randomization~* uncontrolled hypertension~* prior history (within 12 weeks prior to randomization) of acute myocardial ischemia, hospitalization for congestive heart failure, myocardial infarction, stroke or transient ischemic attack~* prior history (within 6 months prior to randomization) of thromboembolism

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Darbepoetin Alfa QW (Type: EXPERIMENTAL): Participants received darbepoetin alfa once a week (QW) for 24 weeks. The initial dose was 0.45 μg/kg; thereafter, active doses were administered to achieve and then maintain hemoglobin levels within a target range of 10.0 to 12.0 g/dL. Participants not on dialysis or who were receiving peritoneal dialysis were administered darbepoetin alfa subcutaneously; participants receiving hemodialysis were administered darbepoetin alfa intravenously.
- Darbepoetin Alfa Q2W (Type: EXPERIMENTAL): Participants received darbepoetin alfa every 2 weeks (Q2W) and a placebo every other 2 weeks to maintain the blind for 24 weeks. The initial dose was 0.75 μg/kg; thereafter, active doses were administered to achieve and then maintain hemoglobin levels within a target range of 10.0 to 12.0 g/dL. Participants not on dialysis or who were receiving peritoneal dialysis were administered darbepoetin alfa subcutaneously; participants receiving hemodialysis were administered darbepoetin alfa intravenously.

Based on this trial design, predict the completion outcome and termination type (if applicable).